S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Inari Medical Stock Forecast, Price & News

+3.10 (+3.73 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume545,755 shs
Average Volume564,434 shs
Market Capitalization$4.30 billion
P/E Ratio191.45
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NARI News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Inari Medical logo

About Inari Medical

Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$139.67 million
Cash Flow
$0.34 per share
Book Value
$4.11 per share


Net Income
$13.79 million




Market Cap
$4.30 billion
Next Earnings Date
11/11/2021 (Estimated)
Not Optionable


Overall MarketRank

2.74 out of 5 stars

Medical Sector

47th out of 1,361 stocks

Surgical & Medical Instruments Industry

6th out of 124 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Inari Medical (NASDAQ:NARI) Frequently Asked Questions

Is Inari Medical a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Inari Medical stock.
View analyst ratings for Inari Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Inari Medical?

Wall Street analysts have given Inari Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inari Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Inari Medical?

Inari Medical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,470,000 shares, an increase of 25.6% from the August 15th total of 1,170,000 shares. Based on an average daily trading volume, of 540,600 shares, the days-to-cover ratio is currently 2.7 days. Currently, 4.4% of the shares of the company are sold short.
View Inari Medical's Short Interest

When is Inari Medical's next earnings date?

Inari Medical is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Inari Medical

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Tuesday, August, 10th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.01. The firm had revenue of $63.45 million for the quarter, compared to the consensus estimate of $59.64 million. Inari Medical had a net margin of 12.02% and a trailing twelve-month return on equity of 12.10%. The company's quarterly revenue was up 149.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.16) EPS.
View Inari Medical's earnings history

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical updated its FY 2021 earnings guidance on Tuesday, September, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million-$255 million, compared to the consensus revenue estimate of $246.95 million.

What price target have analysts set for NARI?

5 brokerages have issued 12-month price objectives for Inari Medical's stock. Their forecasts range from $110.00 to $135.00. On average, they expect Inari Medical's stock price to reach $126.20 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts' price targets for Inari Medical
or view top-rated stocks among Wall Street analysts.

Who are Inari Medical's key executives?

Inari Medical's management team includes the following people:

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Honeywell International (HON), The Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), The Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

When did Inari Medical IPO?

(NARI) raised $110 million in an IPO on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

What is Inari Medical's stock symbol?

Inari Medical trades on the NASDAQ under the ticker symbol "NARI."

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Hamilton Lane Advisors LLC (0.05%) and Wedbush Securities Inc. (0.01%). Company insiders that own Inari Medical stock include Andrew Hykes, Ansbert Gadicke, Cynthia L Lucchese, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Mitch C Hill, Presidio Management Group X Ll, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends for Inari Medical

Which major investors are selling Inari Medical stock?

NARI stock was sold by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC. Company insiders that have sold Inari Medical company stock in the last year include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Presidio Management Group X Ll, Stanley Tang, Thomas Tu, and William Hoffman.
View insider buying and selling activity for Inari Medical
or view top insider-selling stocks.

Which major investors are buying Inari Medical stock?

NARI stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Inari Medical stock in the last two years include Andrew Hykes, Cynthia L Lucchese, Mitch C Hill, Presidio Management Group X Ll, and William Hoffman.
View insider buying and selling activity for Inari Medical
or or view top insider-buying stocks.

How do I buy shares of Inari Medical?

Shares of NARI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inari Medical's stock price today?

One share of NARI stock can currently be purchased for approximately $86.15.

How much money does Inari Medical make?

Inari Medical has a market capitalization of $4.30 billion and generates $139.67 million in revenue each year. The company earns $13.79 million in net income (profit) each year or $0.27 on an earnings per share basis.

How many employees does Inari Medical have?

Inari Medical employs 456 workers across the globe.

What is Inari Medical's official website?

The official website for Inari Medical is www.inarimedical.com.

Where are Inari Medical's headquarters?

Inari Medical is headquartered at 9 Parker Suite 100, Irvine CA, 92618.

How can I contact Inari Medical?

Inari Medical's mailing address is 9 Parker Suite 100, Irvine CA, 92618. The company can be reached via email at [email protected].

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.